Association between stomatitis and treatment efficacy with novel TROP2-directed antibody drug conjugate (ADC), datopotamab deruxtecan, in patients with metastatic cancer

被引：0
|
作者：
Abelman, Rachel O.
Spring, Laura M.
Ryan, Phoebe K.
Fell, Geoffrey
Juric, Dejan
Heist, Rebecca S.
Bardia, Aditya
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5459
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5459
引用
收藏
页数：2
相关论文
共 50 条
  • [31] SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results
    Starodub, Alexander N.
    Ocean, Allyson J.
    Shah, Manish A.
    Vahdat, Linda T.
    Chuang, Ellen
    Guarino, Michael J.
    Picozzi, Vincent J.
    Thomas, Sajeve S.
    Maliakal, Pius P.
    Govindan, Serengulam V.
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2014, 74 (19)
  • [32] Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)
    Gray, Jhanelle E.
    Heist, Rebecca S.
    Starodub, Alexander N.
    Camidge, D. Ross
    Kio, Ebenezer
    Masters, Gregory
    Purcell, W. Thomas
    Guarino, Michael J.
    Misleh, Jamal
    Schneider, Charles J.
    Schneider, Bryan J.
    Ocean, Allyson J.
    Johnson, Tirrell
    Gandhi, Leena
    Kalinsky, Kevin
    Govindan, Serengulam V.
    Maliakal, Pius
    Mudenda, Boyd
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77
  • [33] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results
    Bardia, A.
    Diamond, J. R.
    Mayer, I. A.
    Isakoff, S. J.
    Abramson, V.
    Starodub, A. N.
    O'Shaughnessy, J.
    Kalinsky, K.
    Moroose, R.
    Shah, N.
    Juric, D.
    Shapiro, G. I.
    Guarino, M.
    Ocean, A. J.
    Messersmith, W. A.
    Berlin, J. D.
    Wegener, W. A.
    Sharkey, R. M.
    Goldenberg, D. M.
    Vahdat, L. T.
    CANCER RESEARCH, 2017, 77
  • [34] Treatment for metastatic platinum resistant urothelial cancer (PRUC) with an anti-Trop2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience
    Tagawa, Scott T.
    Faltas, Bishoy
    Lam, Elaine
    Messersmith, Wells A.
    Saylor, Philip
    Bardia, Aditya
    Hajdenberg, Julio J.
    Morgans, Alicia K.
    Berlin, Jordan D.
    Lim, Emerson
    Kalinsky, Kevin
    Maliakal, Pius
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    Ocean, Allyson J.
    CANCER RESEARCH, 2016, 76
  • [35] Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer
    Niculescu-Duvaz, Ion
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (03) : 350 - 360
  • [36] Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).
    Camidge, D. Ross
    Heist, Rebecca Suk
    Masters, Gregory A.
    Scheff, Ronald J.
    Starodub, Alexander
    Messersmith, Wells A.
    Bardia, Aditya
    Ocean, Allyson J.
    Horn, Leora
    Berlin, Jordan
    Maliakal, Pius P.
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    Guarino, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors
    Sharkey, Robert M.
    Ocean, Allyson J.
    Starodub, Alexander N.
    Bardia, Aditya
    Guarino, Michael
    Messersmith, Wells A.
    Berlin, Jordan D.
    Picozzi, Vincent J.
    Moroose, Rebecca
    Wegener, William A.
    Maliakal, Pius
    Govindan, Serengulam V.
    Goldenberg, David M.
    CANCER RESEARCH, 2017, 77
  • [38] BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of triple negative breast cancer
    Tang, W.
    Huang, X.
    Ou, Z.
    Yan, H.
    Gan, J.
    Dong, Q.
    Tan, B.
    Yang, Y.
    Guo, Y.
    Li, S.
    Thomas, B.
    Yu, J-C
    CANCER RESEARCH, 2019, 79 (04)
  • [39] Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC
    Bardia, A.
    Diamond, J. R.
    Mayer, I. A.
    Starodub, A. N.
    Moroose, R. L.
    Isakoff, S. J.
    Ocean, A. J.
    Guarino, M. J.
    Berlin, J. D.
    Messersmith, W. A.
    Thomas, S. S.
    O'Shaughnessy, J. A.
    Kalinsky, K.
    Maurer, M.
    Chang, J. C.
    Forero, A.
    Traina, T.
    Gucalp, A.
    Wilhelm, F.
    Wegener, W. A.
    Maliakal, P.
    Sharkey, R. M.
    Goldenberg, D. M.
    Vahdat, L. T.
    CANCER RESEARCH, 2016, 76
  • [40] YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy
    Shang, Chengzhang
    Yang, Liu
    Zhang, Jiyong
    Han, Yanfei
    Li, Zhuolin
    Han, Zhenyan
    Li, Jun
    Meng, Ying
    An, Gao
    Yang, Hao
    An, Wenqian
    Chen, Lei
    Charpentier, John
    CANCER RESEARCH, 2022, 82 (12)
12345